These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12234333)

  • 21. Angiotensin converting enzyme inhibitors in nondiabetic renal disease.
    Maschio G; Marcantoni C
    Curr Opin Nephrol Hypertens; 1998 May; 7(3):253-7. PubMed ID: 9617554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Uncritical acceptance of combination treatment of angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor in nondiabetic renal disease trial results.
    Griffin KA; Bidani AK
    Hypertension; 2009 Jan; 53(1):e3; author reply e4. PubMed ID: 19047576
    [No Abstract]   [Full Text] [Related]  

  • 23. Is intensive management of blood pressure to prevent visual loss in persons with type 2 diabetes indicated?
    Klein R
    Arch Ophthalmol; 2004 Nov; 122(11):1707-9. PubMed ID: 15534135
    [No Abstract]   [Full Text] [Related]  

  • 24. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y; Takenaka T; Nakamura T; Suzuki H
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
    Matsuda H; Hayashi K; Saruta T
    J Hum Hypertens; 2003 Apr; 17(4):271-6. PubMed ID: 12692572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Further evidence for the renoprotective effect of ACE inhibitors: ramipril protects against the progression of chronic renal insufficiency in non-diabetic nephropathy with nephrotic proteinuria].
    Mayr M; Dickenmann MJ
    Schweiz Med Wochenschr; 2000 Apr; 130(13):491. PubMed ID: 10812646
    [No Abstract]   [Full Text] [Related]  

  • 27. Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney diseases.
    Seeman T; Dusek J; Vondrák K; Flögelová H; Geier P; Janda J
    Am J Hypertens; 2004 May; 17(5 Pt 1):415-20. PubMed ID: 15110900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal and cardiovascular effects of angiotensin-converting enzyme inhibitor plus angiotensin II receptor antagonist therapy in children with proteinuria.
    Lubrano R; Soscia F; Elli M; Ventriglia F; Raggi C; Travasso E; Scateni S; Di Maio V; Versacci P; Masciangelo R; Romero S
    Pediatrics; 2006 Sep; 118(3):e833-8. PubMed ID: 16923922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
    Luna E; Cerezo I; Macias R; Villa J; Martinez C; Cubero J; Martinez R; Ferreira F; García C
    Transplant Proc; 2011; 43(6):2187-90. PubMed ID: 21839229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypertension with co-existing renal disease.
    Bauer JH; Reams GP
    J Hum Hypertens; 1990 Dec; 4 Suppl 5():27-34. PubMed ID: 2090835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Diabetes mellitus, hypertension and kidney].
    Monhart V
    Vnitr Lek; 2008 May; 54(5):499-504, 507. PubMed ID: 18630636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiotensin-I converting enzyme inhibition: clinical effects in chronic renal disease.
    de Jong PE; Heeg JE; Apperloo AJ; de Zeeuw D
    Am J Kidney Dis; 1991 May; 17(5 Suppl 1):85-8. PubMed ID: 2024682
    [No Abstract]   [Full Text] [Related]  

  • 33. [ACE inhibitors and the kidney].
    Hörl WH
    Wien Med Wochenschr; 1996; 146(11):231-4; discussion 234-5. PubMed ID: 8928521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of angiotensin-converting enzyme inhibitors in nondiabetic advanced renal disease.
    Adarkwah CC; Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2011 Apr; 11(2):215-23. PubMed ID: 21476823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteinuria in special populations: pregnant women and children.
    Hladunewich MA; Schaefer F
    Adv Chronic Kidney Dis; 2011 Jul; 18(4):267-72. PubMed ID: 21782133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Control of arterial pressure in diabetic nephropathy].
    Luño J; García de Vinuesa S
    Nefrologia; 2001; 21(3):240-5. PubMed ID: 11471304
    [No Abstract]   [Full Text] [Related]  

  • 37. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease.
    Chrysostomou A; Becker G
    N Engl J Med; 2001 Sep; 345(12):925-6. PubMed ID: 11565535
    [No Abstract]   [Full Text] [Related]  

  • 38. Halting the progression of renal disease: where we stand?
    Campbell RC; Remuzzi G
    Nefrologia; 2002; 22(4):303-5. PubMed ID: 12369119
    [No Abstract]   [Full Text] [Related]  

  • 39. Angiotensin blockade as sole treatment for proteinuric kidney disease in children.
    Chandar J; Abitbol C; Montané B; Zilleruelo G
    Nephrol Dial Transplant; 2007 May; 22(5):1332-7. PubMed ID: 17299000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antihypertensive treatment and glomerular size selectivity in hypertensive patients with renal parenchymal disease and proteinuria.
    Shand BI; Lewis JG; Elder PA; Agarwal M
    Clin Nephrol; 2002 Oct; 58(4):321-4. PubMed ID: 12400851
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.